fac-Tris(di­methyl sulfoxide-κO)tris­(thio­cyanato-κN)iron(III)

The title complex adopts a fac-octa­hedral coordination environment around the central Fe^III atom with three O-bonded dimethyl sulfoxide ligands and three N-bonded iso­thio­cyanate ligands.

(2-Amino­cyclo­hexanol-κ²N,O)chlorido(η⁶-p-cy­mene)ru­thenium(II) tetra­fluoro­borate (2-amino­cyclo­hexanolato-κ²N,O)chlorido(η⁶-p-cymene)ru­thenium(II)

The title compound crystallizes with one neutral Ru^II species, one cationic Ru^II species and a BF₄⁻ counter-ion in the asymmetric unit. Both Ru^II centres adopt the expected piano-stool geometry, with the η⁶-p-cymene ligand forming the seat and the chlorido and bidentate amino-alcohol-derived ligands occupying the remaining coordination sites.

2-(2-Meth­oxy­phen­yl)-4,5-bis­(4-methyl­phen­yl)-1H-imidazol-3-ium 2,4,6-tri­nitro­phenolate

The title imidazolium picrate salt crystallizes in the triclinic space group P1. The asymmetric unit consists of one imidazolium cation and one picrate anion. There is an intra­molecular N—H⋯O hydrogen bond within the imidazolium cation and an inter­molecular N—H⋯O hydrogen bond between the imidazolium cation and the picrate anion. In the crystal, the ions are further associated through π–π stacking inter­actions,

3-(4-Chloro­phen­yl)-3-hy­droxy-1-phenyl­prop-2-ene-1-thione

In the title compound, the dihedral angle between the aromatic rings is 13.06 (6)° and an intra­molecular O—H⋯S hydrogen bond supports the mol­ecular conformation. In the extended structure, weak C—H⋯O hydrogen bonds connect the mol­ecules into [010] chains.

1,1′-(2,2-Di­phenyl­ethene-1,1-di­yl)bis­(3,5-di­methyl-1H-pyrazol-2-ium) dichloride

The title compound crystallizes in the triclinic space group P1. The ethene derivative is substituted by two phenyl groups in 2-position and two 3,5-di­methyl­pyrazolinium units in 1-position, which makes this alkene into a dication. Two chloride ions act as counter-ions in the crystal structure and are linked via N—H⋯Cl and C—H⋯Cl inter­actions with the alkene. The crystal structure features a three-dimensional network stabilized by N—H⋯Cl, C—H⋯Cl and C—H⋯π inter­actions.

2-[(3-Chloro-2-methyl­phen­yl)amino]­quinoline-3-carb­oxy­lic acid

Single crystals of 2-[(3-chloro-2-methyl­phen­yl)amino]­quinoline-3-carb­oxy­lic acid were obtained from slow evaporation of an ethyl acetate solution. In the crystal, the mol­ecules pair up to form acid–acid homodimers.

N-Phenyl-[1,1′-biphen­yl]-2-carboxamide

The title mol­ecule contains a carboxamide fragment in which the amide N atom is bonded to a phenyl group, while the carbonyl C atom is attached to a biphenyl unit. In the crystal, mol­ecules are linked by N—H⋯O hydrogen bonds, forming chains running parallel to the a axis. These chains are further connected by C—H⋯π inter­actions, resulting in a three-dimensional supra­molecular network.

Ethyl 3-hy­droxy­benzoate

The title compound, C₉H₁₀O₃, was synthesized through a Fischer esterification: the crystal comprises two independent mol­ecules with essentially the same planar structures.

2,4,5-Tris(4-methyl­phen­yl)-1H-imidazol-3-ium 2,4,6-tri­nitro­phenolate

The crystal structure of the title imidazolium picrate salt is consolidated by N—H⋯O hydrogen bonds and multiple offset π–π stacking contacts between neighbouring aromatic rings; the nitro-group oxygen atoms of the picrate anion are positionally disordered.

rac-1-(2-{[(Benz­yloxy)carbon­yl]amino}­cyclo­hex­yl)pyrrolidin-1-ium chloride

The crystal structure of C₁₉H₂₆N₂O₂⁺·Cl⁻, an inter­mediate in the synthesis of the selective κ-opioid receptor agonist U50,488, is reported. The compound crystallizes as a centrosymmetric structure with both (S,S)- and (R,R)-enanti­omers in the unit cell. In the crystal, the chloride ion facilitates the formation of enanti­omeric pairs through N—H⋯Cl hydrogen bonds.

2-(3,4-Di­chloro­phen­yl)-N-methyl-N-[2-(pyrrolidin-1-yl)cyclo­hex­yl]acetamide hydro­chloride: (±)-U50,488H

The crystal structure of the methanol-solvated hydro­chloride salt of the selective κ-opioid receptor agonist (±)-U50,488 is reported. The compound crystallized as a racemate of the (S,S) and (R,R) enanti­omers, consistent with the anti-selective nucleophilic substitution used in its synthesis. This study provides the first structural characterization of the hydro­chloride salt form of this widely used pharmacological compound.